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not receiving β-blockers. The first reason for non-prescription was presumed
contra-indication in 51.9% (177 pts). This contra-indication was asthma or
COPD in 71%, symptomatic hypotension in 15%, bradycardia in 12% and
other problems in 8% . The second reason for non prescribing β-blockers was
previous side effects in 35.2% (120 pts) including heart failure decompensa-
tion in 39%, symptomatic hypotension in 36%, asthenia in 26%, bradycardia
in 18%, impotence in 5% and others in 6%. Lastly, in 10.9% of patients
without β-blockers, the reason for non prescription was fear of potential side
effect.
Conclusion: Respiratory disease remains the main reason for not pre-
scribing β-blockers in CHF despite the fact that selective β-blockers are now
recommended in this population. Room remains for improvement in β-blockers
prescription rate in CHF patients with concomitant COPD, underscoring the
importance of pursuing education of cardiologists.
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Introduction: The multivalvular endocarditis is rare, frequently involving
two valves, and is associated with bad prognosis.
Objective: To compare clinical, microbiological and in hospital prognostic
of multivalvular infective endocarditis with single valve infective endocarditis.
Methods and patients:This is a retrospective study; included 225 patients
admitted between 2001 and 2005 for management of infective endocarditis.
Subsequently, our population was divided into two groups: Group 1: multival-
vular patients (29 patients), Group 2: monovalvular patients (196 patients).
Results: Group1’s patients were younger. Most of patients of two groups
had underlying heart disease, essentially rheumatic heart disease.
In group1, there is more mitral insufficiency, more aortic insufficiency
(p=0.002), but less aortic stenosis. Groups’ 1 patients have more mechanical
valves prosthesis (p=0,004). The germ most frequently involved was the sta-
phylococcus in case of multivalvular disease (46.7% vs 37.3%) and strepto-
coccus in case of monovalvular disease (26.7% vs 38.2%), but without a
significant difference in the both cases. The localization of vegetations in multi
valvular IE were: mitro aortic in 25 cases.
In the TTE, there are more vegetations in group 1 :(p=0,048). Vegetations
with size between 10 and 15 mm are more frequent in the group 1(p=0,019).
Valvular perforations are more frequent (p=0,070). Evolution to valvular
abscess (p=0,414), and acute pericardial effusion (p=0,051) was more frequent
in group 1.
During their hospital period, urgent surgical indication was more frequent
in the group 1(62, 1% vs. 51, 3%; p=0,279), with more frequent hemodynamic
indication (72, 2% vs. 47%; p=0,049). Hospital mortality is higher in the
group 1 (21, 4% vs. 17, 2%; p=0,586), but without a statistical significance.
Conclusion: Mutivalvular endocarditis has specific characteristics: Staphy-
lococcus is the more incriminated germ. It is associated to more complications,
and necessitates more urgent surgery because of acute left heart failure.
084
Additive role of beta blockade in determining positive response to car-
diac resynchronization therapy
Isabella Kardasz, Gabriele Borelli, Paola Bendinelli, Lorenzo Rondinini,
Giulio Zucchelli, Maria Grazia Bongiorni, Rita Mariotti
University of Pisa, Cardiothoracic and Vascular Department, Pisa, Italie
Cardiac resynchronization therapy (CRT) and beta blockers (BB) are
effective in advanced heart failure (HF). Often, due to side effects, BB are
not used or dose not increased. We evaluated the titration of BB therapy
with carvedilol (Carv) in CRT Responders (R) and Not Responders (NR),
recruiting 65 HF outpatients (pts) with CRT indication and on optimal treat-
ment [70% males; age 67.9±12.6 years, ys; NYHA 2.7±0.7; aetiology 44%
coronary artery disease (CAD), 43% dilated cardiomyopathy (DCM)]. All
underwent ECG, echocardiography, NYHA evaluation before and after 1 y
of CRT. Considering NYHA response and improvement of systolic left ven-
tricular function (EF,%), R (ΔNYHA> 1 and/or ΔEF> 5%) and NR were
defined. During follow-up, Carv was titrated. Basally R and NR were sim-
ilar for age, sex, HF aetiology (R 40% CAD, 42.5% DCM; NR 48% CAD,
40% DCM), QRS duration (168±32 vs 178±29 msec), end-diastolic (EDV,
ml), end-systolic (ESV) volume, EF (R 25.1±7.9 NR 27.4±8.2), BB treat-
ment (85 vs 88%) and Carv dose (16.3±18.6 vs 13.2±10.3 mg/day). Only
basal NYHA (R 2.9±0.7 NR 2.4±0.6, p=0.002) was significantly different.
There was no significant difference in QRS duration postCRT (R 123±32,
NR 127±36 msec). After 1 y, R showed greater variation of EDV and ESV
(ΔEDV -45±46 vs -2±56 p=0.01; ΔESV -46±46 vs -1±45 p=0.003) and
mitral regurgitation entity (-0.5±0.7 vs 0±0.7 p=0.02). After 1 y there was
an overall increase of pts on BB (92.5 vs 92%), but R achieved a greater
Carv dose (25.1±20.4 vs 14.5±7.3 mg/day p=0.002, Δdose 8.7±11 vs
1.2±10.7 p=0.009). Carv dose increase and EF improvement were correlated
(r=0.40, p=0.02), while dose increase and ventricular remodeling (LVR)
were negatively related (ΔEDV r=0.42 p=0.02; ΔESV r=0.45 p=0.01). In
both groups CRT allows to introduce and augment BB dose, but only in R
dose increase is statistically significant, correlating with LVR regression.
Such results suggest an addictive role of BB titration in determining CRT
positive response.
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Rationale: HF treatment is often started during hospitalisation. It
appeared interesting to describe the evolution of treatment after hospital
discharge.
Objectives: To describe changes in HF treatment since hospital discharge
after stratification on the time elapsed between discharge and beginning of the
survey.
Methods: Cross sectional observational survey with retrospective collec-
tion of data at hospital discharge. Patients must have been diagnosed with HF
and have been hospitalised for HF within the previous 18 months.
Results: 1452 HF patients met the inclusion criteria and started the survey.
1170 (67% males, age 72±11 years, LVEF 40%±13%) have had at least one
visit by the cardiologist between hospital discharge and entry in the survey.
Patients were stratified according to the time since hospital discharge (<3
months N=414, 3-6 months N=297, 6-12 months N=296, 12 to 18 months
N=163). At hospital discharge, recommended betablocker, ACEI (of which
perindopril) or ARB, are prescribed respectively to 826 (70,6%), 807 (69,0%)
and 170 (14,5%) patients. Target doses were reached in 87 (10.5%) patients
with betablocker, 411 (50.9%) patients with ACEI, 7 (4.1%) patients with
ARB and 417 (43.4%) patients with either ACEI or ARB. At start of the
survey, target doses were reached in 176 patients (20.4%) treated with
betablockers, 470 patients (59.6%) treated with ACEI, 16 patients (7.2%)
receiving ARB and 484 patients (49.7%) receiving either ACEI or ARB. Rates
of patients reaching the target dose for betablockers increased significantly
with time (from 19.5% to 29.8% p=0.01). No significant changes were noticed
for ACEI or ARB.
Conclusion: Treatment strategies for Heart Failure started at hospital are
well followed and amplified by French outhospital cardiologists after hospital
discharge.
